Biomarkers for Disease Severity in Children Infected With Respiratory Syncytial Virus: A Systematic Literature Review
Author:
Öner Deniz1, Drysdale Simon B234, McPherson Calum2, Lin Gu-Lung2, Janet Sophie2, Broad Jonathan2, Pollard Andrew J2, Aerssens Jeroen1, Nair Harish, Campbell Harry, Openshaw Peter, Beutels Philippe, Bont Louis, Pollard Andrew, Molero Eva, Martinon-Torres Federico, Heikkinen Terho, Meijer Adam, Fischer Thea Kølsen, van den Berge Maarten, Giaquinto Carlo, Demont Clarisse, Gallichan Scott, Dormitzer Philip, Leach Amanda, Dillon Laura, Aerssens Jeroen, Rosen Brian, Nair Harish, Campbell Harry, Openshaw Peter, Beutels Philippe, Bont Louis, Pollard Andrew, Molero Eva, Martinon-Torres Federico, Heikkinen Terho, Meijer Adam, Fischer Thea Kølsen, van den Berge Maarten, Giaquinto Carlo, Demont Clarisse, Gallichan Scott, Dormitzer Philip, Leach Amanda, Dillon Laura, Aerssens Jeroen, Rosen Brian,
Affiliation:
1. Infectious Diseases Translational Biomarkers, Janssen Pharmaceutica, Beerse, Belgium 2. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom 3. National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom 4. Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, St George’s, University of London, London, United Kingdom
Abstract
Abstract
Background
Clinical manifestations of respiratory syncytial virus (RSV) infection vary widely from mild, self-limiting illness to severe life-threatening disease. There are gaps in knowledge of biomarkers to objectively define severe disease and predict clinical outcomes.
Methods
A systematic search was performed, 1945–March 2019 in databases Ovid Medline, Embase, Global health, Scopus, and Web of Science. Risk of bias was assessed using the Cochrane tool.
Results
A total of 25 132 abstracts were screened and studies were assessed for quality, risk of bias, and extracted data; 111 studies met the inclusion criteria. RSV severity was correlated with antibody titers, reduced T and B cells, dysregulated innate immunity, neutrophil mobilization to the lungs and blood, decreased Th1 response, and Th2 weighted shift. Microbial exposures in respiratory tract may contribute to neutrophil mobilization to the lungs of the infants with severe RSV compared with mild RSV disease.
Conclusions
Although a wide range of biomarkers have been associated with RSV disease severity, robust validated biomarkers are lacking. This review illustrates the broad heterogeneity of study designs and high variability in the definition of severe RSV disease. Prospective studies are required to validate biomarkers. Additional research investigating epigenetics, metabolomics, and microbiome holds promise for novel biomarkers.
Funder
Innovative Medicines Initiative 2 Joint Undertaking European Union Horizon 2020 Research and Innovation Programme European Federation of Pharmaceutical Industries and Associations
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|